Cargando…

Molecular markers as therapeutic targets in lung cancer

Lung cancer is responsible for 29% of cancer deaths in the United States and has very low 5-year survival rates of approximately 11% in men and 15% in women. Although the early diagnosis of lung cancer may increase the survival rate with adequate treatment, advanced lung cancers are often metastasiz...

Descripción completa

Detalles Bibliográficos
Autores principales: Tseng, Hsin-Hui, He, Biao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sun Yat-sen University Cancer Center 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845617/
https://www.ncbi.nlm.nih.gov/pubmed/23369726
http://dx.doi.org/10.5732/cjc.013.10011
_version_ 1782293337984729088
author Tseng, Hsin-Hui
He, Biao
author_facet Tseng, Hsin-Hui
He, Biao
author_sort Tseng, Hsin-Hui
collection PubMed
description Lung cancer is responsible for 29% of cancer deaths in the United States and has very low 5-year survival rates of approximately 11% in men and 15% in women. Although the early diagnosis of lung cancer may increase the survival rate with adequate treatment, advanced lung cancers are often metastasized and receive limited benefit from therapeutic regimens. As conventional treatments for lung cancer reach their limitations, researchers have attempted to discover novel drug therapies aimed at specific targets contributing to the progression of tumorigenesis. Recent advances in systems biology have enabled the molecular biology of lung Carcinogenesis to be elucidated. Our understanding of the physiologic processes of tumor development provide a means to design more effective and specific drugs with less toxicity, thereby accelerating the delivery of new drug therapies to the patient's bedside.
format Online
Article
Text
id pubmed-3845617
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Sun Yat-sen University Cancer Center
record_format MEDLINE/PubMed
spelling pubmed-38456172013-12-11 Molecular markers as therapeutic targets in lung cancer Tseng, Hsin-Hui He, Biao Chin J Cancer Editorial Lung cancer is responsible for 29% of cancer deaths in the United States and has very low 5-year survival rates of approximately 11% in men and 15% in women. Although the early diagnosis of lung cancer may increase the survival rate with adequate treatment, advanced lung cancers are often metastasized and receive limited benefit from therapeutic regimens. As conventional treatments for lung cancer reach their limitations, researchers have attempted to discover novel drug therapies aimed at specific targets contributing to the progression of tumorigenesis. Recent advances in systems biology have enabled the molecular biology of lung Carcinogenesis to be elucidated. Our understanding of the physiologic processes of tumor development provide a means to design more effective and specific drugs with less toxicity, thereby accelerating the delivery of new drug therapies to the patient's bedside. Sun Yat-sen University Cancer Center 2013-02 /pmc/articles/PMC3845617/ /pubmed/23369726 http://dx.doi.org/10.5732/cjc.013.10011 Text en Chinese Journal of Cancer http://creativecommons.org/licenses/by-nc-sa/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License, which allows readers to alter, transform, or build upon the article and then distribute the resulting work under the same or similar license to this one. The work must be attributed back to the original author and commercial use is not permitted without specific permission.
spellingShingle Editorial
Tseng, Hsin-Hui
He, Biao
Molecular markers as therapeutic targets in lung cancer
title Molecular markers as therapeutic targets in lung cancer
title_full Molecular markers as therapeutic targets in lung cancer
title_fullStr Molecular markers as therapeutic targets in lung cancer
title_full_unstemmed Molecular markers as therapeutic targets in lung cancer
title_short Molecular markers as therapeutic targets in lung cancer
title_sort molecular markers as therapeutic targets in lung cancer
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845617/
https://www.ncbi.nlm.nih.gov/pubmed/23369726
http://dx.doi.org/10.5732/cjc.013.10011
work_keys_str_mv AT tsenghsinhui molecularmarkersastherapeutictargetsinlungcancer
AT hebiao molecularmarkersastherapeutictargetsinlungcancer